Relationships between high-sensitive C-reactive protein and markers of arterial stiffness in hypertensive patients. Differences by sex

Manuel A Gomez-Marcos1*, Jose I Recio-Rodriguez1, Maria C Patino-Alonso1, Cristina Agudo-Conde1, Leticia Gomez-Sanchez1, Emiliano Rodriguez-Sanchez1, Marta Gomez-Sanchez1, Vicente Martinez-Vizcaino2 and Luis Garcia-Ortiz1

Abstract

Background: The present study was designed to evaluate the relationship between high-sensitivity C-reactive protein (hs-CRP) and arterial stiffness according to sex in patients with arterial hypertension.

Methods: A case-series study was carried out in 258 hypertensive patients without antecedents of cardiovascular disease or diabetes mellitus. Nephelometry was used to determine hs-CRP. Office or clinical and home blood pressures were measured with a validated OMRON model M10 sphygmomanometer. Ambulatory blood pressure monitoring was performed with the SpaceLabs 90207 system. Pulse wave velocity (PWV) and central and peripheral augmentation index (AIx) were measured with the Sphygmocor system, and a Sonosite Micromax ultrasound unit was used for automatic measurements of carotid intima-media thickness (IMT). Ambulatory arterial stiffness index and home arterial stiffness index were calculated as “1-slope” from the within-person regression analysis of diastolic-on-systolic ambulatory blood pressure.

Results: Central and peripheral AIx were greater in women than in men: 35.31 ± 9.95 vs 26.59 ± 11.45 and 102.06 ± 20.47 vs 85.97 ± 19.13, respectively. IMT was greater in men (0.73 ± 0.13 vs 0.69 ± 0.10). hs-CRP was positively correlated to IMT (r = 0.261), maximum (r = 0.290) and to peripheral AIx (r = 0.166) in men, and to PWV in both men (r = 0.280) and women (r = 0.250). In women, hs-CRP was negatively correlated to central AIx (r = −0.222). For each unit increase in hs-CRP, carotid IMT would increase 0.05 mm in men, and PWV would increase 0.07 m/sec in men and 0.08 m/sec in women, while central AIx would decrease 2.5 units in women. In the multiple linear regression analysis, hs-CRP explained 10.2% and 6.7% of PWV variability in women and men, respectively, 8.4% of carotid IMT variability in men, and 4.9% of central AIx variability in women.

Conclusions: After adjusting for age, other cardiovascular risk factors and the use of antihypertensive and lipid-lowering drugs, hs-CRP was seen to be positively correlated to carotid IMT in men, and negatively correlated to central AIx in women. The association of hs-CRP to arterial stiffness parameters differs between men and women.

Keywords: Hypertension, High-sensitive C-reactive protein, Arterial stiffness
Background
The association of high-sensitivity CRP (hs-CRP) to cardiovascular morbidity-mortality has not been sufficiently clarified. Some studies have identified hs-CRP as an independent predictor of cardiovascular events, hypertension and diabetes [1-3]. It offers prognostic information additional to that of the classical factors used to estimate cardiovascular risk, and reclassifies a substantial proportion of “intermediate risk” individuals as presenting high risk [3,4]. Kaptoge et al. [5], in a metaanalysis of 160,309 patients without antecedents of cardiovascular disease, concluded that hs-CRP concentration shows a continuous association to the risk of coronary disease, cerebral thrombosis and cardiovascular mortality. Nevertheless, this association is conditioned by the conventional cardiovascular risk factors. However, its role in the pathogenesis of arteriosclerosis has not been demonstrated [1,6-8].

The studies that analyze the relationship between hs-CRP and arterial stiffness, as well as behavior according to sex, are inconclusive [9-11]. A prospective study in males subjected to 20 years of follow-up has concluded that pulse wave velocity (PWV) is related to cumulative exposure to hs-CRP, while the augmentation index (AIx) is more related to the values present at the time of analysis [12]. Regarding the relationship between hs-CRP and intima-media thickness (IMT), a number of studies have reported a positive correlation, particularly in hypertensive elderly individuals [8,13], while another study has only found an association in women [14]. The association of the different arterial stiffness measures to hs-CRP and its behavior according to sex in hypertensive individuals have not been studied to date. The present study was designed to evaluate the relationship between hs-CRP and arterial stiffness as evaluated by carotid IMT, PWV, central and peripheral AIx, ambulatory arterial stiffness index (AASI) and home arterial stiffness index (HASI) according to sex in patients with primary arterial hypertension.

Methods
Study design and population
A cross-sectional study was carried out in a primary care setting. We consecutively included all hypertensive subjects visiting primary care clinics between January 2008 and January 2011, and referred to the research unit for the assessment of cardiovascular risk. Hypertension was diagnosed when the mean of three recordings in the clinic under basal conditions and separated in time revealed systolic blood pressure (SBP) ≥140 and/or diastolic blood pressure (DBP) ≥ 90 mmHg. On each visit at least two recordings were made, spaced more than one minute apart. The included 258 hypertensive patients were aged 30–80 years without history of cardiovascular disease (ischemic heart disease or stroke) or diabetes mellitus. Sample size calculation indicated that the 258 patients included in the study were sufficient to detect a minimum correlation coefficient between hs-CRP and arterial stiffness parameters of 0.20 in a two-sided test, with a significance level of 0.05 and a power of 0.90. The study was approved by an independent ethics committee of Salamanca University Hospital (Spain), and all participants gave written informed consent according to the general recommendations of the Declaration of Helsinki [15].

Measurement
The clinical, anthropometric and analytical data collected are shown in Table 1. The measurement procedure has been described previously [16]. Hs-CRP was determined by the nephelometric method (Beckman Instrument APS; Beckman Coulter Inc., Fullerton, CA, USA) [17].

Blood pressure
Office or clinical blood pressure
Measurement was obtained by performing three measurements of systolic (SBP) and diastolic blood pressure (DBP), using the average of the last two, with a validated OMRON model M10 sphygmomanometer (Omron Health Care, Kyoto, Japan), and following the recommendations of the European Society of Hypertension [18]. The mean of the last two measurements obtained by the nurse of the research unit from the arm with high blood pressure was used for the study.

Home blood pressure (HBP)
Three measurements were made in the morning (between 6:00 and 9:00 a.m.), and three in the afternoon/evening (between 6:00 and 9:00 p.m.), over a period of 7 days, with a minimum interval of one minute between measurements, and excluding the first measurement and the values corresponding to the first day of measurement [19]. The same sphygmomanometer model used to measure blood pressure in the office was employed.

Ambulatory blood pressure monitoring (ABPM)
ABPM was performed on a day of standard activity, with an adequate cuff for the size of the patient’s arm. A control system (Spacelabs 90207, Healthcare, Issaquah, Washington, USA), validated according to the protocol of the British Hypertension Society, was used [20]. The records of readings considered to be valid were ≥ 80% of the total. The monitor was programmed for obtaining blood pressure measurements every 20 min during the waking period and every 30 min during the resting period. Individual correction was made of the waking and sleeping hours reported by the patient.
Table 1 Characteristics of study patients, overall and by sex

| Variable                        | Overall (n = 258) | Males (n = 153) | Females (n = 105) | P value |
|---------------------------------|------------------|----------------|------------------|---------|
| Age (years)                     | 53.27 ± 12.01    | 52.18 ± 12.20  | 54.85 ± 11.60    | 0.080   |
| Serum glucose (mg/dl)           | 87.69 ± 10.80    | 88.16 ± 11.53  | 86.99 ± 9.61     | 0.398   |
| Glycated hemoglobin (%)         | 5.05 ± 0.54      | 5.06 ± 0.58     | 5.02 ± 0.48      | 0.566   |
| Office BP (mmHg)                |                  |                |                  |         |
| SBP                             | 139.93 ± 16.75   | 141.35 ± 15.90 | 137.84 ± 17.81   | 0.099   |
| DBP                             | 88.34 ± 10.69    | 88.33 ± 10.53  | 88.37 ± 10.98    | 0.975   |
| Pulse pressure                  | 52.23 ± 12.82    | 53.61 ± 12.70  | 50.20 ± 12.79    | 0.036   |
| Heart rate                      | 72.37 ± 12.89    | 70.09 ± 12.62  | 75.74 ± 12.60    | 0.001   |
| ABPM 24 hours (mmHg)            |                  |                |                  |         |
| SBP                             | 126.71 ± 12.83   | 127.66 ± 12.20 | 125.31 ± 13.63   | 0.149   |
| DBP                             | 78.72 ± 9.86     | 80.13 ± 9.58   | 76.65 ± 9.93     | 0.005   |
| Pulse pressure                  | 47.99 ± 9.50     | 47.53 ± 8.53   | 48.66 ± 10.76    | 0.348   |
| Heart rate                      | 71.92 ± 10.62    | 71.03 ± 11.47  | 73.24 ± 9.11     | 0.103   |
| Home BP (mmHg)                  |                  |                |                  |         |
| SBP                             | 127.23 ± 14.49   | 128.69 ± 13.55 | 125.11 ± 15.58   | 0.051   |
| DBP                             | 81.62 ± 9.85     | 81.92 ± 9.45   | 81.19 ± 10.43    | 0.557   |
| Pulse pressure                  | 45.60 ± 10.07    | 46.77 ± 9.01   | 43.91 ± 11.26    | 0.026   |
| Heart rate                      | 68.62 ± 9.17     | 67.35 ± 8.98   | 70.45 ± 9.18     | 0.007   |
| Current smokers (%)             | 64 (24.8)        | 46 (30.1)      | 18 (17.1)        | 0.018   |
| Obesity (%) *                   | 70 (27.1)        | 45 (29.4)      | 25 (23.8)        | 0.320   |
| BMI (kg/m²)                     | 27.92 ± 3.83     | 28.30 ± 3.20   | 27.37 ± 4.55     | 0.054   |
| Waist circumference (cm)        | 95.60 ± 11.12    | 99.45 ± 9.14   | 90.03 ± 11.41    | p < 0.001 |
| Dyslipidemia (%)                | 206 (79.8)       | 121 (79.1)     | 85 (81.0)        | 0.633   |
| Total cholesterol (mg/dL)       | 208.96 ± 36.94   | 205.37 ± 35.13 | 214.27 ± 39.02   | 0.059   |
| Triglycerides (mg/dL)           | 126.34 ± 73.35   | 135.95 ± 85.98 | 112.17 ± 45.96   | 0.011   |
| LDL-cholesterol (mg/dL)         | 130.64 ± 33.00   | 129.59 ± 30.35 | 132.17 ± 36.62   | 0.546   |
| HDL-cholesterol (mg/dL)         | 53.28 ± 13.01    | 48.90 ± 10.94  | 59.73 ± 13.16    | p < 0.001 |
| No HDL-cholesterol (mg/dL)      | 155.75 ± 36.48   | 156.50 ± 35.41 | 154.64 ± 38.15   | 0.692   |
| Atherogenic index               | 4.12 ± 1.13      | 4.39 ± 1.19    | 3.73 ± 0.92      | p < 0.001 |
| Cardiovascular risk             | 15.29 ± 12.52    | 19.19 ± 14.15  | 9.55 ± 6.19      | p < 0.001 |
| DAgostino                       |                  |                |                  |         |
| hs-CRP (mg/L)                   | 2.73 ± 4.02      | 2.94 ± 4.81    | 2.41 ± 2.37      | 0.310   |
| Fibrinogen, g/L                 | 317.05 ± 61.39   | 314.57 ± 63.55 | 320.69 ± 58.21   | 0.441   |
| Maximum IMT (mm)                | 0.88 ± 0.14      | 0.90 ± 0.15    | 0.86 ± 0.11      | 0.012   |
| Mean IMT (mm)                   | 0.71 ± 0.12      | 0.73 ± 0.13    | 0.69 ± 0.10      | 0.011   |
| PWV (m/sec)                     | 8.65 ± 2.06      | 8.66 ± 2.14    | 8.64 ± 1.96      | 0.952   |
| CAIx                            | 30.12 ± 11.66    | 26.59 ± 11.45  | 35.31 ± 9.95     | p < 0.001 |
| PAIx                            | 92.52 ± 21.19    | 85.97 ± 19.13  | 102.06 ± 20.47   | p < 0.001 |
| AASI                            | 0.37 ± 0.06      | 0.37 ± 0.06    | 0.38 ± 0.06      | 0.050   |
| AASI-BPVR                       | 0.16 ± 0.16      | 0.15 ± 0.17    | 0.18 ± 0.13      | 0.101   |
| Awake-AASI                      | 0.37 ± 0.06      | 0.37 ± 0.05    | 0.38 ± 0.06      | 0.061   |
| Sleep-AASI                      | 0.38 ± 0.15      | 0.38 ± 0.14    | 0.39 ± 0.16      | 0.534   |
| HASI                            | 0.59 ± 0.18      | 0.58 ± 0.20    | 0.61 ± 0.15      | 0.365   |
Table 1 Characteristics of study patients, overall and by sex (Continued)

|                      | Overall | Men | Women | p-value |
|----------------------|---------|-----|-------|---------|
| HASI-BPVR            | 0.29 ± 0.24 | 0.25 ± 0.26 | 0.35 ± 0.19 | 0.001   |
| Antihypertensive Drugs (%) | 101 (39.1) | 61 (39.9) | 40 (38.1) | 0.774   |
| Lipid-lowering Drugs (%) | 48 (18.6) | 31 (20.3) | 17 (16.2) | 0.409   |

Data for qualitative variables are expressed as n (%) and quantitative variables as mean ± standard deviation.

* Obesity: BMI ≥ 30 Kg/m² or Waist circumference ≥ 88 cm in men and ≥ 102 cm in women; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; AMBP: Ambulatory blood pressure monitoring; BMI: body mass index; hs-CRP: high-sensitive C-reactive protein; HDL: high density lipoprotein; LDL: low density lipoprotein; IMT: Intima-Media Thickness; PWV: pulse wave velocity; CAIx: Central augmentation index; PAIx: Peripheral augmentation index, AASI: Ambulatory arterial stiffness index, BPVR: Blood pressure variability ratio; HASI: Home arterial stiffness index.

Vascular assessment

Assessment of carotid intima-media thickness (IMT)

Carotid ultrasound to assess IMT was performed by two investigators trained for this purpose before starting the study. The reliability of assessment was evaluated before the study, using the intraclass correlation coefficient, which showed values of 0.974 (95%CI: 0.935 to 0.990) for intra-investigator agreement on repeated measurements in 20 subjects, and 0.897 (95%CI: 0.740 to 0.959) for inter-investigator agreement. According to the Bland-Altman analysis, the limit of inter-investigator agreement was 0.022 (95%CI: -0.053 to 0.098), and the limit of intra-investigator agreement was 0.012 (95%CI: -0.034 to 0.059). A Sonosite Micromax ultrasound device paired with a 5–10 MHz multifrequency high-resolution linear transducer with Sonocap software was used for performing automatic measurements of CC-IMT, obtained automatically 120 values, 10 measurements in each of the 12 projections, in order to optimize reproducibility. Measurements were made of the common carotid artery after the examination of a longitudinal section of 10 mm at a distance of 1 cm from the bifurcation, performing measurements in the near wall, and in the far wall in the lateral, anterior and posterior projections, following an axis perpendicular to the artery to discriminate two lines - one for the intima-blood interface and the other for the media-adventitia interface. Using mean average values and maximum average values calculated automatically by the software. The measurements were obtained with the subject lying down, with the head extended and slightly turned opposite to the exploratory side, following the recommendations of the Manheim Carotid Intima-Media Thickness Consensus [21].

Pulse wave velocity (PWV) and peripheral (PAIx) and central (CAIx) augmentation index

Were estimated through the SphygmoCor System (AtCor Medical Pty Ltd Head Office, West Ryde, Australia). Using the SphygmoCor System (Px Pulse Wave Analysis) by an investigator, with the patient in the sitting position and resting the arm on a rigid surface, pulse wave analysis was made with a sensor in the radial artery, using mathematical transformation to estimate the aortic pulse wave. The reliability of which was evaluated before the study began using the CAIx intra-class correlation coefficient, which showed values of 0.974 (95%CI: 0.936 to 0.989) for intra-observer agreement on repeated measurements in 22 subjects and according to the Bland-Altman analysis the limits of intra-observer agreement was 0.454 (95%CI: -9.876 to 10.785). From the morphology of the aortic wave, Central AIx was estimated using the following formula: Increase in central pressure × 100/pulse pressure. Peripheral AIx was calculated as follows: (second peak systolic blood pressure [SBP2] – diastolic blood pressure [DBP])/ (first peak SBP-DBP) × 100 (%). Using the SphygmoCor System (Vx pulse wave velocity), and with the patient in the supine position, the pulse wave of the carotid and femoral arteries was analyzed, estimating the delay with respect to the ECG wave and calculating the PWV. Distance measurements were taken with a measuring tape from the sternal notch to the carotid and femoral arteries at the sensor location.

Ambulatory arterial stiffness index (AASI) and home arterial stiffness index (HASI)

For AASI and HASI estimation, the regression slope of diastolic on systolic blood pressure was computed for each individual on the basis of 24-hour ABPM (AASI) and also HBP readings (HASI) over 6 days. AASI as well as HASI were defined as one minus the respective regression slope of DBP on SBP. AASI was also computed from waking or sleeping blood pressure. Blood pressure variability ratio (BPVR) was defined as SD (SBP)/SD (DBP), AASI (BPVR) as 1-[1/SD (SBP)/SD (DBP)] in 24-hour blood pressure [22-24], and HASI (BPVR) as 1-[1/SD (SBP)/SD (DBP)] over 7 days of HBP recording.

The individuals performing the different tests were blinded to the clinical data of the patient. All organ damage assessment measures were made within a period of 10 days.

Statistical analysis

Continuous variables were expressed as the mean ± standard deviation (SD), while frequency distributions were used for qualitative variables. The difference in means between two-category quantitative variables has been analyzed using the Student t-test for independent
samples and Ji Square for qualitative variables. Pearson’s correlation coefficient was used to estimate the relationship between quantitative variables. We performed linear regression analysis using high-sensitive C-reactive protein as independent variables and using IMT, PWV and CAIx as dependent variables. We have performed multiple linear regression analysis with interaction effects (between gender and hs-CRP) using IMT, PWV and CAIx as dependent variables and high-sensitive C-reactive protein as independent variables, establishing 7 models: model 1, without adjusted; model 2, adjusting for gender and interaction gender x hs-CRP, model 3, adding age; model 4, adding the waist circumference; model 5, adding 24 hours SBP and 24 hours heart rate; model 6, adding Atherogenic Index (Atherogenic Index = Total cholesterol/HDL-cholesterol); model 7, adding Antihypertensive and Lipid-lowering Drugs. We performed multiple linear regression analysis using IMT,

### Table 2 Correlation of arterial stiffness measurement and high-sensitive C-reactive protein

| Variable                        | Overall (n = 258) | Males (n = 153) | Females (n = 105) |
|---------------------------------|-------------------|-----------------|-------------------|
| **Office BP (mmHg)**            |                   |                 |                   |
| SBP                             | 0.048             | 0.038           | 0.054             |
| DBP                             | 0.040             | 0.045           | 0.031             |
| Pulse pressure                  | 0.026             | −0.004          | 0.060             |
| Heart rate                      | 0.186**           | 0.206*          | 0.189             |
| **ABPM 24 hours (mmHg)**        |                   |                 |                   |
| SBP                             | 0.126*            | 0.196*          | 0.023             |
| DBP                             | 0.055             | 0.161*          | −0.125            |
| Pulse pressure                  | 0.115             | 0.100           | 0.145             |
| Heart rate                      | 0.246**           | 0.306**         | 0.144             |
| **Home BP (mmHg)**              |                   |                 |                   |
| SBP                             | 0.185**           | 0.212**         | 0.138             |
| DBP                             | 0.137*            | 0.188*          | 0.047             |
| PP                              | 0.134*            | 0.123           | 0.142             |
| Heart rate                      | 0.189**           | 0.200*          | 0.196             |
| Total cholesterol (mg/dL)       | −0.004            | 0.044           | −0.060            |
| LDL-cholesterol (mg/dL)         | 0.063             | 0.094           | 0.031             |
| HDL-cholesterol (mg/dL)         | −0.198**          | −0.138          | −0.282**          |
| No HDL-cholesterol (mg/dL)      | 0.063             | 0.083           | 0.034             |
| Atherogenic Index               | 0.171**           | 0.141           | 0.211*            |
| Ln Cardiovascular risk DAgostino| 0.188**           | 0.238**         | 0.086             |
| Waist circumference (cm)        | 0.235**           | 0.215**         | 0.275**           |
| Maximum IMT (mm)                | 0.194**           | 0.290**         | 0.011             |
| Mean IMT (mm)                   | 0.174**           | 0.261**         | 0.010             |
| PWV (m/sec)                     | 0.280**           | 0.250**         | 0.319**           |
| CAIx                            | −0.048            | 0.067           | −0.222*           |
| PAIx                            | 0.068             | 0.166*          | −0.058            |
| AASI                            | 0.067             | −0.027          | 0.215*            |
| AASI-BPVR                       | −0.012            | 0.012           | −0.049            |
| Awake-AASI                      | 0.057             | −0.034          | 0.198             |
| Sleep-AASI                      | 0.093             | 0.005           | 0.240*            |
| HASI                            | −0.013            | −0.044          | 0.057             |
| HASI-BPVR                       | −0.049            | −0.059          | 0.004             |

BP: Blood pressure; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; ABPM: Ambulatory blood pressure monitoring; HDL: High density lipoprotein; LDL: Low density lipoprotein; IMT: Intima Media Thickness; PWV: Pulse Wave Velocity; CAIx: Central augmentation index; PAIx: Peripheral augmentation index; AASI: Ambulatory arterial stiffness index; BPVR: Blood pressure variability ratio; HASI: Home arterial stiffness index.
PWV and CAIx as dependent variables and high-sensitive C-reactive protein as independent variables, establishing 6 models: model 1, without adjusted; model 2, adjusting for age; model 3, adding the waist circumference; model 4, adding SBP, ABPM 24 hours and heart rate 24 hours; model 5, adding Atherogenic Index; model 6, adding Antihypertensive and Lipid-lowering Drugs. All analyzes were performed by gender and variables not normally distributed we used the neperian logarithm (LN). The data were analyzed using the SPSS version 18.0 statistical package (SPSS Inc., Chicago, Illinois, USA).

Results
The clinical characteristics, cardiovascular risk factors, blood pressure values, IMT, PWV, CAIx, PAIx, AASI, HASI and antihypertensive and lipid-lowering drugs considered globally and by sexes are reported in Table 1. Women showed higher central and peripheral AIx values and home arterial stiffness index-blood pressure variability ratio (HASI-BPVR) values, while men showed greater cardiovascular risk and common carotid IMT values, without differences in hs-CRP.

Table 2 reflects the correlation among hs-CRP, risk factors and IMT, PWV, CAIx, PAIx, AASI, HASI considered globally and according to sexes. Ambulatory systolic (SBP) and diastolic blood pressure (DBP), cardiovascular risk estimated from the Framingham equation, mean and minimum IMT, and peripheral AIx (PAIx) were positively correlated to hs-CRP in men. In women, HDL-cholesterol and central AIx (CAIx) were negatively correlated, while the atherogenic index and ambulatory arterial stiffness index (AASI) (24 hours and resting) were positively correlated to hs-CRP. Waist circumference and PWV showed positive correlations in both sexes.

Figure 1 shows the simple linear regression straight lines of hs-CRP as independent variable and IMT maximum, PWV and AIx as dependent variables. For each unit increase in hs-CRP, carotid IMT would increase...
0.05 mm in men, with practically no changes in women ($\beta = 0.002, p = 0.918$), while PWV would increase 0.07 m/sec in men and 0.08 m/sec in women. Lastly, for each unit increase in hs-CRP, the CAIx would decrease 2.5 units in women.

The interaction analysis, showed that the effect of hs-CRP toward IMT maximum and CAIx depends of the gender ($P < 0.05$) (Table 3).

The multiple linear regression models showed that in males, 8.4% ($\beta = 0.049$) of the variability of IMT could be explained by hs-CRP – statistical significance being maintained after the adjustments made in the different models ($R^2 = 0.545$, beta 0.026 and $p = 0.016$). In men, 6.7% of the variability of PWV could be explained by hs-CRP ($\beta = 0.066$), versus 10.2% in women ($\beta = 0.078$). Statistical significance was maintained after

| Variable | $\beta$ | P Value | 95%CI  | $R^2$ | Adjusted $R^2$ |
|----------|--------|---------|--------|-------|----------------|
| IMT maximum |
| Model 1 | 0.031 | 0.002 | 0.011 to 0.052 | 0.037 |
| Model 2 | 0.002 | 0.923 | $-0.030$ to 0.034 | 0.060 |
| Model 3 | $-0.009$ | 0.432 | $-0.033$ to 0.014 | 0.491 |
| Model 4 | $-0.011$ | 0.368 | $-0.035$ to 0.013 | 0.486 |
| Model 5 | $-0.007$ | 0.549 | $-0.031$ to 0.016 | 0.516 |
| Model 6 | $-0.010$ | 0.413 | $-0.033$ to 0.014 | 0.527 |
| Model 7 | $-0.008$ | 0.502 | $-0.032$ to 0.016 | 0.525 |
| PWV |
| Model 1 | 0.070 | 0.000 | 0.040 to 0.100 | 0.078 |
| Model 2 | 0.070 | 0.000 | 0.040 to 0.101 | 0.071 |
| Model 3 | 0.050 | 0.000 | 0.025 to 0.075 | 0.371 |
| Model 4 | 0.043 | 0.001 | 0.018 to 0.069 | 0.377 |
| Model 5 | 0.028 | 0.035 | 0.002 to 0.054 | 0.432 |
| Model 6 | 0.027 | 0.043 | 0.001 to 0.053 | 0.442 |
| Model 7 | 0.027 | 0.046 | 0.000 to 0.053 | 0.440 |
| CAIx |
| Model 1 | $-0.617$ | 0.455 | $-2.241$ to 1.006 | 0.002 |
| Model 2 | $-2.511$ | 0.044 | $-4.956$ to $-0.066$ | 0.131 |
| Model 3 | $-2.983$ | 0.010 | $-5.253$ to $-0.713$ | 0.254 |
| Model 4 | $-2.587$ | 0.025 | $-4.845$ to $-0.329$ | 0.247 |
| Model 5 | $-2.420$ | 0.032 | $-4.626$ to $-0.214$ | 0.315 |
| Model 6 | $-2.453$ | 0.031 | $-4.675$ to $-0.231$ | 0.311 |
| Model 7 | $-2.711$ | 0.017 | $-4.937$ to $-0.486$ | 0.322 |

Model 1: C-reactive protein.
Model 2: Adjusted by Gender and interaction gender x hs-CRP. Gender (coded 1 for male and 0 for female).
Model 3: Adjusted by Model 2 and age.
Model 4: Adjusted by Model 3 and waist circumference.
Model 5: Adjusted by Model 4 and 24 hours systolic blood pressure (SBP) and 24 hours Heart rate.
Model 6: Adjusted by Model 5 and atherogenic Index.
Model 7: Adjusted by Model 6 and Antihypertensive and Lipid-lowering Drugs.
Interaction gender x hs-CRP IMT maximum: Model 2 ($p = 0.023$); Model 3 ($p = 0.011$); Model 4 ($p = 0.010$) Model 5 ($p = 0.012$); Model 6 ($p = 0.009$); Model 7 ($p = 0.013$).
Interaction gender x hs-CRP CAIx: Model 2 ($p = 0.035$); Model 3 ($p = 0.042$); Model 4 ($p = 0.050$); Model 5 ($p = 0.019$); Model 6 ($p = 0.020$); Model 7 ($p = 0.015$).
In the PWV, the interactions gender x hs-CRP, were not statistically significant.
adjusting for age in men (beta = 0.040; p = 0.019), but was lost in the next model with waist circumference. In contrast, in women statistical significance was maintained to adjustment of the fourth model (age, waist circumference, 24-hour SBP and heart rate) (β = 0.043, p = 0.030). In women, 4.9% of the variability of CAIx could be explained by hs-CRP, statistical significance being maintained after adjusting of the different models (β = −3.134, p = 0.009). The association of hs-CRP to the rest of the parameters used to assess arterial stiffness disappeared after adjusting for age (Table 4).

**Discussion**

The present study shows that the correlation of hs-CRP to the IMT, PWV, CAIx, PAIx, AASI, HASI in hypertensive patients behaves differently in men and women. In men, a positive correlation to IMT is observed, while in women a negative correlation to CAIx and a positive correlation to AASI is noted. PWV shows a positive correlation in both sexes. After adjusting for age, waist circumference, 24-hour heart rate and SBP, atherogenic index and the use of antihypertensive and lipid-lowering drugs, the correlation of hs-CRP to carotid IMT in men and to CAIx in women was seen to be maintained. The association to PWV was maintained in men only on adjusting for age, while in women the correlation was maintained with waist circumference, SBP and 24-hour heart rate, after adjusting for age.

In coincidence with the data published by Kaptoge [5], the hs-CRP concentration was higher in males, though CAIx was found to be higher in women than in men, in agreement with other authors [11,25]. The global analysis of the sample revealed correlations between hs-CRP and the different risk factors similar to those published by other investigators [5].

In coincidence with the findings of other studies, mean IMT was greater in men than in women [26]. The association between IMT and hs-CRP only proved significant in men – and this association was maintained after adjusting for the different models used. The studies that have examined the relationship between hs-CRP and carotid IMT in the general population have yielded

**Table 4 Regression models with the high-sensitive C-reactive protein adjusted for each measure of arterial stiffness**

| Variable | Males (n = 153) | Females (n = 105) |
|----------|----------------|-------------------|
|          | β   | Sig. | 95%CI | Adjusted R² | β   | Sig. | 95%CI | Adjusted R² |
| Dependent variable: IMT maximum |
| Model 1 | 0.049 | 0.000 | 0.022 to 0.075 | 0.084 | 0.002 | 0.918 | −0.028 to 0.032 | 0.000 |
| Model 2 | 0.029 | 0.004 | 0.009 to 0.048 | 0.511 | −0.009 | 0.452 | −0.031 to 0.014 | 0.430 |
| Model 3 | 0.025 | 0.013 | 0.005 to 0.045 | 0.508 | −0.007 | 0.546 | −0.031 to 0.016 | 0.425 |
| Model 4 | 0.027 | 0.011 | 0.006 to 0.048 | 0.537 | −0.003 | 0.827 | −0.026 to 0.021 | 0.456 |
| Model 5 | 0.026 | 0.013 | 0.006 to 0.047 | 0.549 | −0.006 | 0.647 | −0.030 to 0.018 | 0.459 |
| Model 6 | 0.026 | 0.016 | 0.005 to 0.046 | 0.545 | −0.003 | 0.782 | −0.028 to 0.021 | 0.454 |
| Dependent variable: PWV |
| Model 1 | 0.066 | 0.001 | 0.026 to 0.106 | 0.067 | 0.078 | 0.001 | 0.031 to 0.124 | 0.102 |
| Model 2 | 0.040 | 0.019 | 0.007 to 0.074 | 0.370 | 0.064 | 0.001 | 0.025 to 0.103 | 0.372 |
| Model 3 | 0.032 | 0.064 | −0.002 to 0.066 | 0.381 | 0.060 | 0.004 | 0.019 to 0.100 | 0.371 |
| Model 4 | 0.020 | 0.254 | −0.015 to 0.056 | 0.412 | 0.043 | 0.030 | 0.004 to 0.081 | 0.482 |
| Model 5 | 0.021 | 0.233 | −0.014 to 0.056 | 0.420 | 0.034 | 0.086 | −0.005 to 0.072 | 0.504 |
| Model 6 | 0.018 | 0.308 | −0.017 to 0.053 | 0.427 | 0.029 | 0.151 | −0.011 to 0.070 | 0.497 |
| Dependent variable: CAIx |
| Model 1 | 0.839 | 0.420 | −1.211 to 2.889 | 0.004 | −2.511 | 0.027 | −4.729 to −0.293 | 0.049 |
| Model 2 | −0.182 | 0.847 | −2.047 to 1.682 | 0.197 | −2.799 | 0.012 | −4.967 to −0.630 | 0.092 |
| Model 3 | 0.020 | 0.983 | −1.837 to 1.877 | 0.172 | −2.476 | 0.031 | −4.718 to −0.235 | 0.094 |
| Model 4 | 1.160 | 0.218 | −0.692 to 3.011 | 0.279 | −2.689 | 0.019 | −4.929 to −0.449 | 0.174 |
| Model 5 | 1.135 | 0.233 | −0.737 to 3.008 | 0.273 | −2.745 | 0.019 | −5.026 to −0.464 | 0.172 |
| Model 6 | 1.130 | 0.238 | −0.757 to 3.017 | 0.270 | −3.134 | 0.009 | −5.456 to −0.812 | 0.204 |

*Model 1: C-reactive protein.*
*Model 2: Adjusted for Age.*
*Model 3: Adjusted for model 2 and Waist circumference.*
*Model 4: Adjusted for model 3 and 24 hours Systolic blood pressure and 24 hours Heart rate.*
*Model 5: Adjusted for model 4 and atherogenic Index.*
*Model 6: Adjusted for model 5 and Antihypertensive and Lipid-lowering Drugs.*
contradictory results. In this sense, not all of them have confirmed that an increase in hs-CRP implies an increase in IMT [27-30]. In this same line, in hypertensive patients some authors have reported a positive association to the development and progression of carotid atherosclerosis [8,31,32], even in cases of recently diagnosed hypertension [33]. However, Choi et al. [34] observed no association between hs-CRP and carotid atherosclerosis in either hypertensive patients or in normotensive individuals. Likewise, the behavior according to patient sex is not clear. In effect, while Makita et al. [27] concluded that in the general population hs-CRP may serve as a surrogate marker for atheroma plaque formation in men but not in women, Sanders et al. [26] found IMT to be significantly associated to hs-CRP in women but not in men, after adjusting for risk factors – the conclusion being that the relationship between hs-CRP and the progression of early carotid atherosclerosis shows gender differences.

Carmel et al. [12], in a prospective study of the association between PWV and hs-CRP, recorded a positive association similar to that seen in the present study, though in this case the behavior between sexes was found to be different after adjustment in the multiple regression analysis. This suggests that inflammation plays a role in aortic stiffness as assessed with PWV, but that patient sex could exert an influence.

In our study, hs-CRP was correlated negative with CAIx in Woman ($r = -0.222$), though Janner et al., in the general population, only observed a relationship in young males [11]. These data coincide with the findings of Carmel et al. [12] in men, where after adjusting in multivariate models only fibrinogen remained as a weak predictor between CAIx and hs-CRP. This relationship, could be explained, by CAIx values are higher in women and decrease with increasing BMI. The BMI may be a confounding factor in this negative correlation of hs-CRP with CAIx.

On the other hand, the disparity of results relating hs-CRP to PWV and CAIx in males reinforces the idea that the findings are not inter-exchangeable and differ according to patient sex [35].

The present study has some limitations, including its cross-sectional design, which does not allow us to establish cause-effect relationships between hs-CRP and the arterial stiffness parameters. In turn, the study population was recruited through consecutive sampling, which precludes generalization of the results. Nevertheless, the distribution of the population analyzed is similar to that of the real-life population of hypertensive subjects with cardiovascular risk factors and no previous cardiovascular disease. Lastly, estimation of the central PWV based on the radial PWV, using the transference function, has been questioned [36-38].

Conclusions

In conclusion, this study shows that after adjusting for age, cardiovascular risk factors and the use of anti-hypertensive and lipid-lowering drugs, hs-CRP exhibits a positive correlation to IMT in men, a negative correlation to CAIx in women, and a positive correlation to PWV in both sexes. Therefore, in order to clarify the role of hs-CRP in relation to the parameters commonly used to assess arterial stiffness in both males and females, prospective studies must be carried out to clarify this association and to define the differences between sexes.

Abbreviations

hs-CRP, High-sensitive CRP; PWV, Pulse wave velocity; Aix, Augmentation index; IMT, Intima-media thickness; AASI, Ambulatory arterial stiffness index; HASI, Home arterial stiffness index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; HBP, Home blood pressure; ABPM, Ambulatory blood pressure monitoring; CAI, Central augmentation index; PAI, Peripheral augmentation index; BPVR, Blood pressure variability ratio.

Competing interests

The authors declare that they have no competing interests associated with this paper.

Authors’ contributions

MAGM devised the study, designed the protocol, participated in fund raising, interpretation of results, prepared the manuscript draft and corrected the final version of the manuscript. JRPP and CAC participated in the study design, data collection and manuscript review. MCPA and VMV performed all analytical methods, interpretation of results, and manuscript review. ERS, LGS and MGK participated in the study design, interpretation of results, and manuscript review. LGO participated in the protocol design, fund raising, analysis of results, and final review of the manuscript. Finally, all authors reviewed and approved the final version of the manuscript.

Acknowledgements

This project was supported by the Regional Health Management of the Castilla and León (SACYL) (GRS 428/A/09 and GRS 498/A/10), Spanish Atherosclerosis Foundation, ISCIII (RD06/018/27) and FEDER.

Author details

1Primary Care Research Unit, La Alamedilla Health Center, Avda. Cornueiros 27, Salamanca 37003, Spain. 2Social and Health Care Research Center, University of Castilla-La Mancha, Calle Altagracia, 50, Cuenca 19071, Spain.

Received: 12 December 2011 Accepted: 16 May 2012
Published: 7 June 2012

References

1. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB: C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99(2):237–242.

2. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347(20):1557–1565.

3. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107(3):363–369.

4. Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007, 49(21):2129–2138.

5. Kapote S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375(9709):132–140.
6. Danesh J, Wheeler JG, Hirschfield GM, Esa D, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350(14):1387–1397.

7. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB: C-reactive protein and coronary heart disease: a critical review. J Intern Med 2006, 264(4):295–314.

8. Rizzo M, Corrado E, Coppola G, Muratori I, Mezzari A, Novo G, Novo S: The predictive role of C-reactive protein in patients with hypertension and subclinical atherosclerosis. Intern Med J 2009, 39(8):539–545.

9. Kampus P, Kals J, Ristomaa T, Fischer K, Zilmer M, Teesalu R: C-reactive protein affects central haemodynamics and augmentation index in apparently healthy persons. J Hypertens 2004, 22(6):1133–1139.

10. Schumacher W, Cockcroft J, Timpson NJ, McEniry CM, Gallacher J, Rumley A, Lowe G, Smith GD, Wilkinson IB, Ben-Shlomo Y: Association between C-reactive protein genotype, circulating levels, and aortic pulse wave velocity. Hypertension 2009, 53(2):150–157.

11. Janner JH, Godtfredsen NS, Laedelund S, Vestbo J, Prescott E: The association between aortic augmentation index and cardiovascular risk factors in a large unselected population. J Hum Hypertens 2011. doi:10.1038/jhh.2011.59.

12. McEniry CM, Spratt M, Munnery M, Yarnell J, Lowe GD, Rumley A, Gallacher J, Ben-Shlomo Y, Cockcroft J, Wilkinson IB: An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the Caerphilly prospective study. Hypertension 2010, 56(1):36–43.

13. Polak JP, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA, D’Agostino RB Sr: Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011, 365(3):213–221.

14. Suh M, Lee JY, Ahn SY, Kim HC, Suh J: C-reactive protein and carotid intima-media thickness in a population of middle-aged Koreans. J Prev Med Public Health 2009, 42(1):29–34.

15. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997, 277(11):925–926.

16. Garcia-Ortiz L, Ramos-Delgado E, Recio-Rodriguez JJ, Agudo-Conde C, Martinez-Salgado C, Patino-Alonso MC, Rodrigue-Sanchez E, Gomez-Marcos MA, Group FeP: Peripheral and central arterial pressure and its relationship to vascular target organ damage in carotid artery, retina and arterial stiffness. Development and validation of a tool. The Vaso risk study. BMC Public Health 2011, 11(1):266.

17. Montagne P, Laroche P, Cuilliere ML, Varin P, Pau B, Duheille J: Microparticle-enhanced nephelometric immunoassay for human C-reactive protein. J Clin Lab Anal 2001, 16(1):24–29.

18. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Grassi G, Sega R: Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e loro Associazioni Study. Hypertension 2007, 49(6):1265–1270.

19. Coca A, Bertomeu F, Dafro A, Esnafiez E, Guillon F, Guerrero L, Listerri JL, Marin-Iranzo R, Megia C, Rodriguez-Manus L, et al. Blood pressure self measurement: Spanish consensus document. Nefrologia 2007, 27(2):139–153.

20. O’Brien E, Petrie J, Littler W, de Swiet M, Padfield PL, O’Donnell CI, MacNee W: Ambulatory arterial stiffness index: reproducibility of different definitions. Am J Hypertens 2010, 23(2):129–134.

21. Van Trijp MJ, Uiterwaal CS, Bos WJ, Oren A, Grobbee DE, Bots ML: Noninvasive arterial measurements of vascular damage in healthy young adults: relation to coronary heart disease risk. Ann Epidemiol 2006, 16(2):71–77.

22. Sander K, Horn CS, Briesenick C, Sander D: High-sensitivity C-reactive protein is independently associated with early carotid artery progression in women but not in men: the INVADE Study. Stroke 2007, 38(1):2881–2886.

23. Makita S, Nakamura M, Hiramori K: The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population. Stroke 2005, 36(10):2138–2142.

24. Ruising Y, Limel Y, Yuming C, Dezhai Y, Weixiong L, Muyan L, Fengping H, Jizhen W, Guangying Y, Zhenbiao N: Prevalence, awareness, treatment, control and risk factors of hypertension in the Guangxi Hei Yi Zhuang and Han populations. Hypertens Res 2006, 29(6):432–435.

25. Takahashi W, Ohruki T, Homma K, Kawada S, Takagi S: The significance of multiple risk factors for early carotid atherosclerosis in Japanese subjects. Intern Med 2007, 46(20):1679–1684.

26. Okazaki S, Furukado S, Abe Y, Tanaka M, Miwa K, Yamagami H, Sakaguchi M, Sakoda S, Kitagawa K: Association of inflammatory markers and carotid intima-media thickness with the risk of cardiovascular events in high-risk patients. Cerebrovasc Dis 2010, 30(2):180–187.

27. Hashimoto H, Kitagawa K, Houjaku H, Etani H, Hori M: Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke 2004, 35(7):1625–1630.

28. Amer MS, Blawarn AE, Khater MS, Omar OH, Mabrouk RA, Tahm HM: Association of high-sensitivity C-reactive protein with carotid artery intima-media thickness in hypertensive older adults. J Am Soc Hypertens 2011, 5(5):395–400.

29. Corrado E, Rizzo M, Muratori I, Coppola G, Novo S: Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type 2 diabetes. Arch Med Res 2008, 39(8):1004–1009.

30. Choi H, Cho DH, Shin HH, Park JB: Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension. Circ J 2004, 68(4):297–303.

31. Laurent S, Cockcroft J, Van Bertel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijk-Boudier H: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27(12):1538–2605.

32. Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, Maughan WL, Kass DA: Estimation of central arterial pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation 1997, 95(7):1827–1836.

33. Segers P, Maheux D, Kips J, Van Bertel LM: The use of a generalized transfer function: different processing, different results? J Hypertens 2007, 25(9):1783–1787.

34. Hope SA, Meredith IT, Cameron JD: Arterial transfer functions and the reconstruction of central aortic waveforms: myths, controversies and misconceptions. J Hypertens 2008, 26(1):4–7.

http://www.biomedcentral.com/1471-2261/12/37

Page 10 of 10

doi:10.1186/1471-2261-12-37

Cite this article as: Gomez-Marcos et al.: Relationships between high-sensitive C-reactive protein and markers of arterial stiffness in hypertensive patients. Differences by sex. BMC Cardiovascular Disorders 2012 12:37.